Explore how claudin-18.2 can transform cancer treatment for gastric and pancreatic tumours using targeted radiotherapy.

From FDA actions to new standard-of-care potential, the breast cancer treatment arsenal continues to expand. This week’s news ...

Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date ...

The FDA has granted priority review to the new drug application (NDA) for gedatolisib, a first-in-class multi-target ...

DNA levels at baseline and during treatment predict response and progression free survival in advanced breast cancer, ...

MD Anderson, Deerfield Management form joint venture to develop targeted cancer treatment Houston-based The University of Texas MD Anderson Cancer Center and Deerfield Management have formed a joint ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, immunotherapies, and emerging antibody–drug conjugates are helping many ...